GlassScriptPhysician profile
David T Garrett
NPI 1316987340
$2,970.42
in general payments reported to CMS, 2019-2025
20 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $445 · 2021: $190 · 2022: $363 · 2023: $495 · 2024: $155 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $630.64 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Clareon |
| Abbvie INC. | $603.04 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $286.17 | 2019-2023 | |
| Allergan, INC. | $261.78 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $151.46 | 2019-2021 | |
| Dompe US, INC. | $144.63 | 2025 | Oxervate |
| Glaukos Corporation | $125.06 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.15 | 2019-2021 | |
| Genentech USA, INC. | $120.74 | 2023 | Vabysmo |
| Ellexiscience | $119.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $111.27 | 2020 | |
| Bausch & Lomb Americas INC. | $104.52 | 2023-2025 | Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $51.14 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $27.85 | 2019 | |
| Rxsight INC | $25.20 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.06 | 2025 | Tecnis Iol |
| Ocular Therapeutix, INC. | $17.08 | 2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $14.51 | 2022 | |
| Harrow Eye, LLC | $14.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.